Trastuzumab - Research Grade Biosimilar, CAS [[180288-69-1]], Unconjugated, Monoclonal

Product Overview

• Article Name: Trastuzumab - Research Grade Biosimilar, CAS [[180288-69-1]], Unconjugated, Monoclonal
• Biozol Catalog Number: PRS-21-854
• Supplier Catalog Number: 21-854
• Alternative Catalog Number: PRS-21-854-0.1
• Manufacturer: ProSci
• Category: Antikörper
• Immunogen: Humanized / ERBB2 (HER2, Tyrosine kinase-type cell surface receptor HER2, MLN19, Metastatic lymph node gene 19 protein, ERBB2, Proto-oncogene Neu, p185erbB2, CD_antigen=CD340, Proto-oncogene c-ErbB-2, MLN 19, NEU, Receptor tyrosine-protein kinase erbB-2,
• Conjugation: Unconjugated
• Alternative Names: NEU, NGL, HER2, TKR1, CD340, HER-2, VSCN2, MLN 19, c-ERB2, c-ERB-2, HER-2/neu

Product Properties

• Clonality: Monoclonal
• Concentration: batch dependent
• NCBI: 2064
• UniProt: P04626
• Buffer: PBS buffer pH 7.5
• Source: CHO cells
• Purity: >95%
• CAS Number: [180288-69-1]

Application Notes

• Application Dilute: For research use only .
• Application Notes: Treatment of HER2-overexpressing breast cancer cell lines with Trastuzumab results in induction of p27KIP1 and the Rb-related protein, p130, which in turn significantly reduces the number of cells undergoing S-phase. A number of other phenotypic changes